were transfected into p80 Jurkat cells (22) by electroporation using a BTX Electro Cell Manipulator 600. After 9 to 24 hours, cells were stimulated with the indicated amount of TNF-␣ for 12 to 16 hours. Cells were then stained for HA expression and propidium iodide uptake. The number of HA-positive cells was scored under constant time, and percent inhibition of apoptosis was calculated by normalizing to the percentage of cell death induced in the HveA⌬CD-HAtransfected samples. Results are representative of three experiments. 28 . We thank P. Scheurich, P. Spear, A. Winoto, and J.
Woronicz (Fig. 1A) (13, 17) . Control experiments showed equal cell surface expression of the wild-type and mutant Fas molecules (18) . Thus, dominant interference cannot be explained by the conventional model of signaling by FasL-induced oligomerization of receptor monomers because, in this scheme, the Pt 2 mutant Fas molecule would not become part of a mixed receptor complex. We therefore tested for ligand-independent interactions between Pt 2 Fas and wild-type Fas. Both full-length and Pt 2 Fas coprecipitated with a Fas 1-210:GFP chimera in which green fluorescent protein (GFP) replaces the death domain (Fig. 1C) . This interaction was specific, because the TNFR family receptors TNFR2/p80 and HveA did not interact with Fas (1).
We have found that TNFR superfamily members share a self-association domain in CRD1, termed the "pre-ligand assembly domain" (PLAD) (Fig. 1B) (19) . To test whether Fas contains a functional PLAD, we constructed hemagglutinin (HA)-tagged NH 2 -terminal Fas truncations (20) . Deleting the first subdomain in CRD1 (amino acids 1 to 42) (21) substantially reduced ligand binding but did not prevent binding of the Fas monoclonal antibody (mAb) APO-1. Deleting the entire CRD1 (amino acids 1 to 66) abrogated binding of both FasL and Fas mAb (Fig. 1A) . Both truncations eliminated coprecipitation with a differentially tagged Fas molecule and abrogated apoptosis signaling; this result indicates that the NH 2 -terminus of Fas, including CRD1, functions as a PLAD (Fig. 1, C and D) (19, 22 (Fig. 1D) .
To further explore the requirement for ligand binding in receptor self-association, we tested the Fas point mutation Arg 86 3 Ser (R86S) that removes a critical CRD2 contact residue for FasL (5) and prevents FasL binding (Fig. 1A) . The overall receptor structure was preserved, as indicated by staining with APO-1 and DX2 Fas mAbs (Fig. 1A) (18) , and self-association with wild-type Fas still occurred (Fig. 1C) . Even though it could not bind FasL, this mutant dominantly interfered with FasL-induced apoptosis through wildtype Fas (Fig. 1E) . Apoptosis induced by Fas mAb in the same cells was unimpaired, which indicated that Fas was functionally expressed on the cell surface (Fig. 1E) (Fig. 2B) . Hence, Fas molecules are in close proximity on the surface of living cells, and this proximity depends on the PLAD.
To test whether native Fas receptors normally self-associate, we performed chemical crosslinking studies on H9 T lymphoma cells expressing endogenous human Fas (Fig. 3) . Crosslinking shifted the apparent molecular size of Fas in deglycosylated cell lysates from 45 to 140 kD under nonreducing conditions (Fig. 3A) . Densitometry suggested that 60% of the Fas chains were crosslinked. Unlike FasL-or Fas mAb-treated cells, Fas complexes from surface-crosslinked cells showed only partial recruitment of FADD and no recruitment of caspase-8, with no cleavage of the downstream caspase substrate poly-(ADP-ribose)polymerase (PARP). Interestingly, crosslinking prevented the formation of active signaling complexes in response to subsequent treatment with agonistic mAb (Fig. 3B) .
Our findings redefine how death signals are triggered through Fas and how mutations in ALPS dominantly interfere with normal Fas function. In a large number of ALPS patients evaluated at the National Institutes of Health (13) (14) (15) 17) , we found that the PLAD was preserved in every example of a dominant-interfering mutation associated with disease, including mutations that create premature termination polypeptides encoding only the first 57 and 62 amino acids of the mature Fas protein.
To cause dominant interference, mutant proteins must physically interact with wildtype proteins in a functional complex (26 ) . Previously, dominant-negative receptor mutations associated with human diseases have been shown to interfere with normal receptor signaling by sequestering ligand, blocking intracellular signaling, or preventing transport of the wild-type chain to the cell surface (27 ) . For Fas, dominant interference stems instead from PLAD-mediated association between wild-type and mutant receptors before ligand binding. PLAD interactions are essential for ligand binding and signaling and have been observed in the regulation of apoptosis by soluble alternatively spliced forms of Fas that all include this domain (28) . PLAD-mediated dominant interference may also play a role in modulation of signaling by decoy receptors (2) and in the pathogenesis of diseases due to heterozygous genetic abnormalities in other members of the TNFR superfamily. chain reaction (PCR) mutagenesis with appropriate primers and Pwo high-fidelity polymerase (Roche Molecular Biochemicals). For the AU-1-tagged receptors, a template with DNA coding for the DTYRYI AU-1 epitope tag sequence previously inserted into the region upstream of Fas CRD1 was used. For HA tagging, mutations were cloned into the Eco RI-Xho I sites of a modified pCDNA3 vector containing the leader sequence of p60 followed by sequences coding for the YPYDVPDYA HA epitope tag. Point mutations were created with the Quickchange technique (Stratagene), substituting Pwo for Pfu polymerase. Mutations were verified by restriction enzyme mapping and automated sequencing. 21. J. H. Naismith and S. R. Sprang, Trends Biochem. Sci.
23, 74 (1998). 22. Murine BW thymoma cell were transfected by electroporation with 10 g of the indicated plasmids and 5 g of the GFP reporter plasmid. After 18 hours, apoptosis was induced with Fas mAb APO-1 (500 ng/ml) or 5% v/v supernatant containing soluble FasL/leucine zipper fusion protein. Viable cell loss was quantitated as described (13 After treatment with the indicated reagents, cells were lysed, immunoprecipitated, and blotted for FADD and caspase-8 as described (15) . The positions of the two isoforms of procaspase-8 ( p54/52) and caspase-8 cleavage products after proteolysis of the p11 caspase subunit ( p43/41) are shown with arrows. PARP cleavage was analyzed on lysates from cells cultured at 37°C for an additional 4 hours after the indicated treatments. The upper band is the 115-kD full-length PARP; the lower band is the 85-kD signature fragment produced by caspase cleavage during apoptosis. The results are representative of at least three independent experiments. 413-nm lasers, respectively. Cells were sequentially illuminated with the 514-and 413-nm lasers so that all three signals could be detected from each cell. Compensation was applied so that there was no FRET signal visible from cells transfected with CFP or YFP alone. We collected 50,000 events from each sample and analyzed the data with the FlowJo software package (Treestar Inc.). Another characteristic of FRET is the dequenching of donor fluorescence after photobleaching of the acceptor. This dequenching can be converted to a measurement of FRET efficiency (E%), which is related to the distance between two molecules by the Förster equation [see (23)]. For FRET efficiency measurements, CFP emission intensities from cotransfected cells were measured on a fluorescence microscope before and after bleaching the YFP with 5 min of illumination through a 505-to 545-nm bandpass filter. We corrected for direct bleaching of cells transfected with the CFP fusion partner alone. FRET efficiencies were calculated using the formula E% ϭ 
